Randall Campbell, PA
Physician Assistant · Ashburn, GANPI 1487868576
Payments from drug & device makers
Across 317 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$874
- GSK$612
- Lilly USA, LLC$549
- Bayer$312
- AbbVie$293
- AstraZeneca$286
- plus $3K from 21 others
What the payments were for
- Food & beverage$5,556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $874 |
| GSK | 34 | $612 |
| Lilly USA, LLC | 38 | $549 |
| Bayer | 13 | $312 |
| AbbVie | 19 | $293 |
| AstraZeneca | 17 | $286 |
| Corcept Therapeutics | 12 | $264 |
| Kowa Pharmaceuticals America, Inc. | 17 | $250 |
| Ironwood Pharmaceuticals, Inc | 16 | $248 |
| Paratek Pharmaceuticals, Inc. | 13 | $240 |
| Novartis | 12 | $230 |
| Dexcom, Inc. | 9 | $202 |
| Amgen | 12 | $188 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $176 |
| Boehringer Ingelheim | 9 | $145 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Merck | 7 | $117 |
| Pfizer | 6 | $97 |
| Medicure Pharma Inc. | 1 | $92 |
| Johnson & Johnson | 4 | $73 |
| Esperion Therapeutics, Inc. | 4 | $58 |
| Eisai Inc. | 1 | $29 |
| Ardelyx, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Abbott | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
How this compares
$5,556 in reported general payments places this provider in the 90th percentile of 3,581 physician assistant providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 211 | $219,599 |
| EliquisApixaban | 98 | $78,216 |
| MounjaroTirzepatide | 64 | $69,890 |
| LinzessLinaclotide | 63 | $57,225 |
| TrulicityDulaglutide | 43 | $52,027 |
| FarxigaDapagliflozin Propanediol | 39 | $49,780 |
| JanuviaSitagliptin Phosphate | 47 | $47,300 |
| KerendiaFinerenone | 48 | $39,251 |
| XareltoRivaroxaban | 47 | $36,100 |
| MyrbetriqMirabegron | 48 | $31,094 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $30,075 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $20,607 |
| TradjentaLinagliptin | 26 | $18,901 |
| JardianceEmpagliflozin | 16 | $18,650 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $18,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $874 | $222,550223 claims |
| Lilly USA, LLCMounjaro, Trulicity | $549 | $121,918107 claims |
| AbbVieLinzess, Namzaric, Viberzi, Creon | $293 | $100,326119 claims |
| PfizerEliquis | $97 | $78,21698 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $612 | $66,81792 claims |
| AstraZenecaFarxiga, Symbicort | $286 | $55,00359 claims |
| MerckJanuvia, Belsomra | $117 | $54,83762 claims |
| BayerKerendia | $312 | $39,25148 claims |
| Boehringer IngelheimTradjenta, Jardiance | $145 | $37,55142 claims |
| Johnson & JohnsonXarelto | $73 | $36,10047 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $31,09448 claims |
| NovartisEntresto | $230 | $18,20326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,581 physician assistant providers in Georgia.
Other physician assistant in Ashburn
- Douglas DiruggieroCartersville$1.3M
- Jennifer CobbsAtlanta$1M
- A BrunnerStockbridge$1M
- Joseph LangshawCalhoun$887K
- Alison MoeAtlanta$410K
- Maggie SchreckAtlanta$389K
- Lisa HillMarietta$190K
- Laura BishopBrunswick$103K
- Jaime AckermanAtlanta$84K
- Richard BurrellBrunswick$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.